Skip to main content
SpringerLink
Log in
Book cover

Liver Anesthesiology and Critical Care Medicine pp 455–468Cite as

Sepsis and Infection

  • Chapter
  • First Online:

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Starzl TE, et al. Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet. 1976;142(4):487–505.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Rubin RH. The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis. 2002;22:125–54.

    PubMed  Google Scholar 

  3. Martin GS, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546–54.

    Article  PubMed  Google Scholar 

  4. Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–5.

    Article  CAS  PubMed  Google Scholar 

  5. Bernstein JM. Treatment of community-acquired pneumonia--IDSA guidelines. Infectious diseases society of America. Chest. 1999;115(3 Suppl):9S–13S.

    Article  CAS  PubMed  Google Scholar 

  6. Jensen WA, et al. Pulmonary complications of orthotopic liver transplantation. Transplantation. 1986;42(5):484–90.

    Article  CAS  PubMed  Google Scholar 

  7. Saner FH, et al. Pulmonary and blood stream infections in adult living donor and cadaveric liver transplant patients. Transplantation. 2008;85(11):1564–8.

    Article  PubMed  Google Scholar 

  8. Singh N, et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. Transplantation. 1994;58(7):774–8.

    Article  CAS  PubMed  Google Scholar 

  9. Wade JJ, et al. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology. 1995;21(5):1328–36.

    Article  CAS  PubMed  Google Scholar 

  10. Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control. 1992;20(5):239–47.

    Article  CAS  PubMed  Google Scholar 

  11. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis. 1988;10(4):677–8.

    Google Scholar 

  12. Singh N, et al. Predicting bacteremia and bacteremic mortality in liver transplant recipients. Liver Transpl. 2000;6(1):54–61.

    CAS  PubMed  Google Scholar 

  13. Nobre V, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.

    Article  CAS  PubMed  Google Scholar 

  14. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly. 2009;139(23–24):318–26.

    CAS  PubMed  Google Scholar 

  15. Schuetz P, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.

    Article  CAS  PubMed  Google Scholar 

  16. van den Broek MA, et al. Procalcitonin as a prognostic marker for infectious complications in liver transplant recipients in an intensive care unit. Liver Transpl. 2010;16(3):402–10.

    Article  PubMed  Google Scholar 

  17. Brodska H, et al. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care. 2009;13(2):R37.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kusne S, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore). 1988;67(2):132–43.

    Article  CAS  Google Scholar 

  19. Neofytos D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–9.

    Article  CAS  PubMed  Google Scholar 

  20. Singh N, et al. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Clin Infect Dis. 1997;24(2):179–84.

    Article  CAS  PubMed  Google Scholar 

  21. Tollemar J, et al. The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc. 1990;22(1):242–4.

    CAS  PubMed  Google Scholar 

  22. Pappas PG, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. 2006;6(2):386–91.

    Article  CAS  PubMed  Google Scholar 

  23. Ergin F, et al. Invasive aspergillosis in solid-organ transplantation: report of eight cases and review of the literature. Transpl Int. 2003;16(4):280–6.

    Article  PubMed  Google Scholar 

  24. Husain S, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation. 2003;75(12):2023–9.

    Article  PubMed  Google Scholar 

  25. Miranda DR, et al. Environment and costs in surgical intensive care unit. The implication of selective decontamination of the digestive tract (SDD). Acta Anaesthesiol Belg. 1983;34(3):223–32.

    CAS  PubMed  Google Scholar 

  26. Arnow PM. Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Infect Dis Clin N Am. 1995;9(4):849–62.

    CAS  Google Scholar 

  27. Bion JF, et al. Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med. 1994;22(1):40–9.

    Article  CAS  PubMed  Google Scholar 

  28. Hellinger WC, et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation. 2002;73(12):1904–9.

    Article  PubMed  Google Scholar 

  29. Zwaveling JH, et al. Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med. 2002;30(6):1204–9.

    Article  PubMed  Google Scholar 

  30. Safdar N, Said A, Lucey MR. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2004;10(7):817–27.

    Article  PubMed  Google Scholar 

  31. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(10):729–37.

    Article  CAS  PubMed  Google Scholar 

  32. Singh N, et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation. 2001;71(7):910–3.

    Article  CAS  PubMed  Google Scholar 

  33. Cruciani M, et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12(5):850–8.

    Article  PubMed  Google Scholar 

  34. Pappas PG, Silveira FP. Candida in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S173–9.

    Article  PubMed  Google Scholar 

  35. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–85.

    Article  Google Scholar 

  36. Asensio A, et al. Colonization and infection with methicillin-resistant Staphylococcus aureus: associated factors and eradication. Infect Control Hosp Epidemiol. 1996;17(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  37. Wertheim HF, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5(12):751–62.

    Article  PubMed  Google Scholar 

  38. Russell DL, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008;8(8):1737–43.

    Article  CAS  PubMed  Google Scholar 

  39. Singh N, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis. 2000;30(2):322–7.

    Article  CAS  PubMed  Google Scholar 

  40. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997;10(4):781–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Rosenthal VD, Maki DG, Graves N. The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control. 2008;36(9):e1–12.

    Article  PubMed  Google Scholar 

  42. Pallin DJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51(3):291–8.

    Article  PubMed  Google Scholar 

  43. Rybak M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98.

    Article  CAS  PubMed  Google Scholar 

  44. Hidayat LK, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138–44.

    Article  PubMed  Google Scholar 

  45. Hutschala D, et al. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology. 2009;111(2):356–65.

    Article  CAS  PubMed  Google Scholar 

  46. Ingram PR, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008;62(1):168–71.

    Article  CAS  PubMed  Google Scholar 

  47. Jeffres MN, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107–15.

    Article  CAS  PubMed  Google Scholar 

  48. Lodise TP, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lodise TP, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–14.

    Article  CAS  PubMed  Google Scholar 

  50. Hong S, et al. Vancomycin-induced acute granulomatous interstitial nephritis: therapeutic options. Am J Med Sci. 2007;334(4):296–300.

    Article  PubMed  Google Scholar 

  51. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007;45(Suppl 3):S184–90.

    Article  CAS  PubMed  Google Scholar 

  52. Calfee DP, et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29(Suppl 1):S62–80.

    Article  PubMed  Google Scholar 

  53. Coia JE, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63(Suppl 1):S1–44.

    Article  PubMed  Google Scholar 

  54. Siegel JD, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10 Suppl 2):S165–93.

    Article  PubMed  Google Scholar 

  55. Singh N, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162(2 Pt 1):505–11.

    Article  CAS  PubMed  Google Scholar 

  56. Patel R, et al. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl. 2001;7(1):27–31.

    Article  CAS  PubMed  Google Scholar 

  57. Paterson DL, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39(1):31–7.

    Article  CAS  PubMed  Google Scholar 

  58. Asensio A, et al. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl. 2008;14(6):799–805.

    Article  PubMed  Google Scholar 

  59. Newell KA, et al. Incidence and outcome of infection by vancomycin-resistant enterococcus following orthotopic liver transplantation. Transplantation. 1998;65(3):439–42.

    Article  CAS  PubMed  Google Scholar 

  60. Nusair A, et al. Infection control experience in a cooperative care center for transplant patients. Infect Control Hosp Epidemiol. 2008;29(5):424–9.

    Article  PubMed  Google Scholar 

  61. McNeil SA, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42(2):195–203.

    Article  PubMed  Google Scholar 

  62. Ghanem G, et al. Outcomes for and risk factors associated with vancomycin-resistant enterococcus faecalis and vancomycin-resistant enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol. 2007;28(9):1054–9.

    Article  CAS  PubMed  Google Scholar 

  63. Babcock HM, et al. Successful treatment of vancomycin-resistant enterococcus endocarditis with oral linezolid. Clin Infect Dis. 2001;32(9):1373–5.

    Article  CAS  PubMed  Google Scholar 

  64. McNeil SA, et al. Successful treatment of vancomycin-resistant enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis. 2000;30(2):403–4.

    Article  CAS  PubMed  Google Scholar 

  65. Munoz P, et al. Linezolid therapy for infective endocarditis. Clin Microbiol Infect. 2007;13(2):211–5.

    Article  CAS  PubMed  Google Scholar 

  66. Swoboda S, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother. 2008;61(3):729–33.

    Article  CAS  PubMed  Google Scholar 

  67. Swoboda S, et al. Septic shock due to vancomycin-resistant enterococci infection. Tigecycline monotherapy. Anaesthesist. 2007;56(2):169–74.

    Article  CAS  PubMed  Google Scholar 

  68. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther. 2008;30(11):2040–50.

    Article  CAS  PubMed  Google Scholar 

  69. Linares L, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc. 2010;42(8):2941–3.

    Article  CAS  PubMed  Google Scholar 

  70. Bert F, et al. Pretransplant fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis. 2012;18(6):908–16.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Aguiar EB, et al. Outcome of bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae after solid organ transplantation. Transplant Proc. 2014;46(6):1753–6.

    Article  CAS  PubMed  Google Scholar 

  72. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997–2000). Int J Antimicrob Agents. 2003;21(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  73. van Duijn PJ, Dautzenberg MJ, Oostdijk EA. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care. 2011;17(6):658–65.

    Article  PubMed  Google Scholar 

  74. Moreno A, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007;7(11):2579–86.

    Article  CAS  PubMed  Google Scholar 

  75. Bodro M, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation. 2015;99(3):616–22.

    Article  CAS  PubMed  Google Scholar 

  76. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. van Duin D, van Delden C, A.S.T.I.D.C.o. Practice. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):31–41.

    Article  CAS  PubMed  Google Scholar 

  79. Kalpoe JS, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18(4):468–74.

    Article  PubMed  Google Scholar 

  80. Swaminathan M, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol. 2013;34(8):809–17.

    Article  PubMed  Google Scholar 

  81. Giannella M, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015;15(6):1708–15.

    Article  CAS  PubMed  Google Scholar 

  82. Pereira MR, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2015;21(12):1511–9.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Souli M, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010;50(3):364–73.

    Article  CAS  PubMed  Google Scholar 

  84. Maltezou HC, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58(3):213–9.

    Article  CAS  PubMed  Google Scholar 

  85. Perez F, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Saidel-Odes L, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol. 2012;33(1):14–9.

    Article  PubMed  Google Scholar 

  87. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358(12):1271–81.

    Article  CAS  PubMed  Google Scholar 

  88. Freire MP, et al. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl Infect Dis. 2014;16(3):369–78.

    Article  CAS  PubMed  Google Scholar 

  89. Zhong L, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation – spectrum and risk factors. J Infect. 2012;64(3):299–310.

    Article  PubMed  Google Scholar 

  90. Ye QF, et al. Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis. 2014;16(5):767–74.

    Article  CAS  PubMed  Google Scholar 

  91. Liu H, et al. Predictors of mortality in solid-organ transplant recipients with infections caused by Acinetobacter baumannii. Ther Clin Risk Manag. 2015;11:1251–7.

    PubMed  PubMed Central  Google Scholar 

  92. Shi SH, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis. 2009;11(5):405–12.

    Article  CAS  PubMed  Google Scholar 

  93. Shields RK, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7(12):e52349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Otan E, et al. Acinetobacter infection in a liver transplantation intensive care unit. Transplant Proc. 2013;45(3):998–1000.

    Article  CAS  PubMed  Google Scholar 

  95. Aydemir H, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22.

    Article  CAS  PubMed  Google Scholar 

  96. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1999;1(4):229–36.

    Article  CAS  PubMed  Google Scholar 

  97. Marr KA, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309–16.

    Article  CAS  PubMed  Google Scholar 

  98. Pappas PG, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.

    Article  CAS  PubMed  Google Scholar 

  99. Groll AH, et al. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr. 1998;210(4):264–73.

    Article  CAS  PubMed  Google Scholar 

  100. Espinel-Ingroff A, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43(8):3884–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Lipp HP. Antifungal agents--clinical pharmacokinetics and drug interactions. Mycoses. 2008;51(Suppl 1):7–18.

    Article  CAS  PubMed  Google Scholar 

  102. Kauffman CA, Carver PL. Update on echinocandin antifungals. Semin Respir Crit Care Med. 2008;29(2):211–9.

    Article  PubMed  Google Scholar 

  103. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med. 2006;355(11):1154–9.

    Article  CAS  PubMed  Google Scholar 

  104. Saner F, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection. 2006;34(6):328–32.

    Article  CAS  PubMed  Google Scholar 

  105. Brown RS Jr, et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation. 1996;61(4):666–9.

    Article  PubMed  Google Scholar 

  106. Kusne S, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis. 1992;166(6):1379–83.

    Article  CAS  PubMed  Google Scholar 

  107. Singh N, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81(3):320–6.

    Article  CAS  PubMed  Google Scholar 

  108. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23(3):608–15.

    Article  CAS  PubMed  Google Scholar 

  109. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore). 1999;78(2):123–38.

    Article  CAS  Google Scholar 

  110. Kwak EJ, et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol. 2004;42(1):435–8.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Herbrecht R, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.

    Article  CAS  PubMed  Google Scholar 

  112. Groetzner J, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008;27(1):1–6.

    Article  PubMed  Google Scholar 

  113. Carby MR, Hodson ME, Banner NR. Refractory pulmonary aspergillosis treated with caspofungin after heart-lung transplantation. Transpl Int. 2004;17(9):545–8.

    CAS  PubMed  Google Scholar 

  114. Denning DW, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5):337–49.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Cornely OA, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.

    Article  CAS  PubMed  Google Scholar 

  116. Ullmann AJ, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.

    Article  CAS  PubMed  Google Scholar 

  117. Walsh TJ, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.

    Article  CAS  PubMed  Google Scholar 

  118. Walsh TJ, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General-, Visceral- and Transplant Surgery, Medical Center University Essen, Essen, Germany

    Fuat Hakan Saner

Authors
  1. Fuat Hakan Saner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fuat Hakan Saner .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, Columbia University Medical Center, New York, New York, USA

    Gebhard Wagener

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saner, F.H. (2018). Sepsis and Infection. In: Wagener, G. (eds) Liver Anesthesiology and Critical Care Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-64298-7_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64298-7_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64297-0

  • Online ISBN: 978-3-319-64298-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation